Article
ESMO: New Trodelvy breast, bladder cancer data show why Gilead's going big for Immunomedics
Rating:
0.0
Views:
130
Likes:
1
Library:
1
Two sets of new data presented at ESMO around Immunomedics' antibody-drug conjugate Trodelvy offer a glimpse into why Gilead paid $21 billion for the biotech. But though the triple-negative breast cancer showing looks like a home run, the bladder cancer results may put the med at a disadvantage as competition heats up.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value